Background
Immune checkpoint blockade (ICB) has revolutionized cancer therapy, yet resistance—both primary and acquired—remains a significant obstacle, affecting the majority of patients.
Methods
Here, we leverage a large-scale, real-worl…
Background
Relapsed or refractory (R/R) B-cell non-Hodgkin’s lymphoma (B-NHL) remains a major therapeutic challenge despite CD19-directed chimeric antigen receptor (CAR) T-cell therapies, with treatment failure often driven by antigen escape and…
Background
Dysbiosis of gut microbiome leads to resistance to immunotherapy in various advanced solid tumors. CJRB-101 is a live biotherapeutic product consisting of a novel strain belonging to the species Leuconostoc mesenteroides. To modulate the tu…
Background
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy has demonstrated substantial clinical benefit in relapsed/refractory multiple myeloma (R/R MM). Nonetheless, immune escape and therapeutic resistance r…
Background
Circadian biology suggests that synchronizing immune checkpoint inhibitor (ICI) dosing with morning peaks in immune activation could improve clinical outcomes, but well-powered studies using appropriate causal inference methodology are spar…
Background
Prostate cancer (PCa) is the second most common malignancy in men worldwide. Although radical prostatectomy effectively controls tumor progression, it often causes complications such as urinary incontinence and sexual dysfunction. Irreversi…
Local immunotherapy has the potential to deliver high doses of immune-potentiating agents with limited systemic toxicity. However, clinical development and implementation have been hindered by numerous challenges. Journal for ImmunoTherapy of Cancer w…
Accumulating evidence from randomized phase 3 trials in multiple tumor types supports the application of neoadjuvant or perioperative immunotherapy to significantly enhance clinical benefit in patients with resectable solid tumors. While systemic immu…
Background
The scarcity of primary conventional dendritic cells (cDCs) and the limited functionality of monocyte-derived dendritic cells (moDCs) have long hindered mechanistic and translational studies in human dendritic cell (DC) biology and immunoth…
Background
Immune checkpoint inhibitors have transformed cancer therapy, yet many patients fail to respond, underscoring the need for complementary strategies. Personalized neoantigen cancer vaccines (NCVs), which stimulate highly specific T-cell resp…
